Competition‐Based Cellular Peptide Binding Assay for HLA Class I

2004 ◽  
Vol 61 (1) ◽  
Author(s):  
Jan H. Kessler ◽  
Willemien E. Benckhuijsen ◽  
Tuna Mutis ◽  
Cornelis J.M. Melief ◽  
Sjoerd H. Burg ◽  
...  
1995 ◽  
Vol 44 (4) ◽  
pp. 189-198 ◽  
Author(s):  
S.H. van der Burg ◽  
E. Ras ◽  
J.W. Drijfhout ◽  
W.E. Benckhuijsen ◽  
A.J.A. Bremers ◽  
...  

1990 ◽  
Vol 172 (3) ◽  
pp. 889-899 ◽  
Author(s):  
J Choppin ◽  
F Martinon ◽  
E Gomard ◽  
E Bahraoui ◽  
F Connan ◽  
...  

The physical association of 40 antigenic peptides and purified HLA class I and class II molecules was monitored using a direct peptide binding assay (PBA) in solid phase and an inhibition peptide binding assay (IPBA) in which the competing peptide was present in a soluble phase. We also examined the ability of different peptides to inhibit the lytic activity of human antiviral cytolytic T cells towards cells incubated with the corresponding target peptide. Our results showed that: (a) Binding of a given human T cell-recognized peptide to several HLA class I and class II molecules occurred frequently. Nevertheless, preferential binding of peptides to their respective restriction molecules was also observed. (b) Binding of HLA molecules to peptides recognized by murine T cells occurred less frequently. (c) 11 of 24 (46%) randomly selected HIV-1 peptides contained agretopic residues allowing their binding to HLA molecules. (d) The kinetics of HLA/peptide association depended on the peptide tested and were faster than or similar to those reported for Ia molecules. Dissociation of these complexes was very low. (e) Peptide/HLA molecule binding was dependent on length, number of positive charges, and presence of hydrophobic residue in the peptide. (f) A correlation was demonstrated between a peptide inhibitory effect in the IPBA and its blocking effect in the cytolytic test. Our data indicated that the restriction phenomenon observed in T cell responses was not strictly related to either an elective HLA/peptide association, or a high binding capacity of a peptide to HLA molecules. These data also showed that the PBA and IPBA are appropriate for the detection of agretopic residues within HIV-1 proteins.


2009 ◽  
Vol 14 (2) ◽  
pp. 173-180 ◽  
Author(s):  
Mikkel Harndahl ◽  
Sune Justesen ◽  
Kasper Lamberth ◽  
Gustav Røder ◽  
Morten Nielsen ◽  
...  

The Human MHC Project aims at large-scale description of peptide-HLA binding to a wide range of HLA molecules covering all populations of the world and the accompanying generation of bioinformatics tools capable of predicting binding of any given peptide to any given HLA molecule. Here, the authors present a homogenous, proximity-based assay for detection of peptide binding to HLA class I molecules. It uses a conformation-dependent anti-HLA class I antibody, W6/32, as one tag and a biotinylated recombinant HLA class I molecule as the other tag, and a proximity-based signal is generated through the luminescent oxygen channeling immunoassay technology (abbreviated LOCI and commercialized as AlphaScreen™). Compared with an enzyme-linked immunosorbent assay—based peptide-HLA class I binding assay, the LOCI assay yields virtually identical affinity measurements, although having a broader dynamic range, better signal-to-background ratios, and a higher capacity. They also describe an efficient approach to screen peptides for binding to HLA molecules. For the occasional user, this will serve as a robust, simple peptide-HLA binding assay. For the more dedicated user, it can easily be performed in a high-throughput screening mode using standard liquid handling robotics and 384-well plates. We have successfully applied this assay to more than 60 different HLA molecules, leading to more than 2 million measurements. ( Journal of Biomolecular Screening 2009:173-180)


2020 ◽  
Vol 21 (4) ◽  
pp. 1119-1135 ◽  
Author(s):  
Shutao Mei ◽  
Fuyi Li ◽  
André Leier ◽  
Tatiana T Marquez-Lago ◽  
Kailin Giam ◽  
...  

Abstract Human leukocyte antigen class I (HLA-I) molecules are encoded by major histocompatibility complex (MHC) class I loci in humans. The binding and interaction between HLA-I molecules and intracellular peptides derived from a variety of proteolytic mechanisms play a crucial role in subsequent T-cell recognition of target cells and the specificity of the immune response. In this context, tools that predict the likelihood for a peptide to bind to specific HLA class I allotypes are important for selecting the most promising antigenic targets for immunotherapy. In this article, we comprehensively review a variety of currently available tools for predicting the binding of peptides to a selection of HLA-I allomorphs. Specifically, we compare their calculation methods for the prediction score, employed algorithms, evaluation strategies and software functionalities. In addition, we have evaluated the prediction performance of the reviewed tools based on an independent validation data set, containing 21 101 experimentally verified ligands across 19 HLA-I allotypes. The benchmarking results show that MixMHCpred 2.0.1 achieves the best performance for predicting peptides binding to most of the HLA-I allomorphs studied, while NetMHCpan 4.0 and NetMHCcons 1.1 outperform the other machine learning-based and consensus-based tools, respectively. Importantly, it should be noted that a peptide predicted with a higher binding score for a specific HLA allotype does not necessarily imply it will be immunogenic. That said, peptide-binding predictors are still very useful in that they can help to significantly reduce the large number of epitope candidates that need to be experimentally verified. Several other factors, including susceptibility to proteasome cleavage, peptide transport into the endoplasmic reticulum and T-cell receptor repertoire, also contribute to the immunogenicity of peptide antigens, and some of them can be considered by some predictors. Therefore, integrating features derived from these additional factors together with HLA-binding properties by using machine-learning algorithms may increase the prediction accuracy of immunogenic peptides. As such, we anticipate that this review and benchmarking survey will assist researchers in selecting appropriate prediction tools that best suit their purposes and provide useful guidelines for the development of improved antigen predictors in the future.


Biochemistry ◽  
2005 ◽  
Vol 44 (37) ◽  
pp. 12491-12507 ◽  
Author(s):  
Rico Buchli ◽  
Rodney S. VanGundy ◽  
Heather D. Hickman-Miller ◽  
Christopher F. Giberson ◽  
Wilfried Bardet ◽  
...  

1993 ◽  
Vol 36 (2) ◽  
pp. 119-127 ◽  
Author(s):  
Nobuyuki Tanigaki ◽  
Doriana Fruci ◽  
Alberto Chersi ◽  
Richard H. Butler
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document